Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Revista Espanola de Enfermedades Digestivas

• Publication date

  2003-08-01

• Fields of study

  Medicine

• Identifiers
  PMID 14510631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Future therapy of hepatitis C

  2002cited by this paper
• Side effects of therapy of hepatitis C and their management

  2002cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

  2001cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• Identification of the major positional isomer of pegylated interferon alpha-2b.

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.

  1997cited by this paper
• Therapy of hepatitis C: Patients with cirrhosis

  1997cited by this paper
• Dose‐dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa

  1997cited by this paper
• Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice.

  1994cited by this paper
• Polyethylene glycol modification of serpins improves therapeutic potential.

  1990cited by this paper
• Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer.

  1990cited by this paper
• Catalytic activity of administered gulonolactone oxidase polyethylene glycol conjugates.

  1989cited by this paper
• Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers.

  1988cited by this paper
• Clinical pharmacology of polyethylene glycol-L-asparaginase.

  1986cited by this paper
• Measurement of 2′,5′-Oligoadenylate Synthetase in Patients Receiving Interferon-Alpha

  1985cited by this paper
• Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.

  1985cited by this paper
• Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates.

  1984cited by this paper
• Physicochemical and biological properties of poly(ethylene glycol)-coupled immunoglobulin G.

  1984cited by this paper
• Properties of two urate oxidases modified by the covalent attachment of poly(ethylene glycol).

  1981cited by this paper
• Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment of polyethylene glycol.

  1981cited by this paper

• Chapter 33 – Introduction of a Biologic Agent into the Clinic

  2010cites this paper
• Synthesis of symmetrically and asymmetrically branched pegylating reagents.

  2008cites this paper
• Synthesis of bis- and tris-branched COOH-terminal pegylating reagents: conjugation to NH-terminal peptides.

  2008cites this paper
• Pharmacokinetic Consequences of Pegylation

  2006influential citation
• The impact of the Orphan Drug Act on drug discovery

  2006cites this paper
• Is screening for interferon retinopathy in hepatitis C justified?

  2004cites this paper